Drugs / REGN10597
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06413680 | Sep 2024 → Feb 2030 expected | clear cell renal carcinoma, melanoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN10597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06413680 ↗ |
| Action | Inhibit | “Anti-PD-1” NCT06413680 ↗ |
| Modality | Protein / enzyme biologic | “Fusion Protein” NCT06413680 ↗ |